0001062993-23-018279.txt : 20230919
0001062993-23-018279.hdr.sgml : 20230919
20230919172542
ACCESSION NUMBER: 0001062993-23-018279
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230915
FILED AS OF DATE: 20230919
DATE AS OF CHANGE: 20230919
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Menold Daniel
CENTRAL INDEX KEY: 0001705745
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36500
FILM NUMBER: 231264760
MAIL ADDRESS:
STREET 1: C/O CYMABAY THERAPEUTICS, INC.
STREET 2: 7575 GATEWAY BLVD., SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CymaBay Therapeutics, Inc.
CENTRAL INDEX KEY: 0001042074
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943103561
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7575 GATEWAY BOULEVARD
STREET 2: SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
BUSINESS PHONE: 510-293-8800
MAIL ADDRESS:
STREET 1: 7575 GATEWAY BOULEVARD
STREET 2: SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX, INC.
DATE OF NAME CHANGE: 20090721
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX INC
DATE OF NAME CHANGE: 19970710
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2023-09-15
0001042074
CymaBay Therapeutics, Inc.
CBAY
0001705745
Menold Daniel
C/O CYMABAY THERAPEUTICS, INC.
7575 GATEWAY BLVD., SUITE 110
NEWARK
CA
94560
0
1
0
0
Vice President, Finance
1
Common Stock
2023-09-15
4
M
0
1545
1.82
A
1545
D
Common Stock
2023-09-15
4
S
0
0
16.8730
D
0
D
Common Stock
2023-09-15
4
M
0
15000
1.72
A
15000
D
Common Stock
2023-09-15
4
S
0
0
16.8730
D
0
D
Employee Stock Option (right to buy)
1.82
2023-09-15
4
M
0
1545
0
D
2026-07-24
Common Stock
1545
0
D
Employee Stock Option (right to buy)
1.72
2023-09-15
4
M
0
15000
0
D
2027-01-18
Common Stock
15000
0
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on April 10, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.44 to $17.09, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares subject to the option became vested and exercisable according to the following schedule: 25% of the shares subject to the option vested on July 22, 2017, and the remaining shares vested in equal monthly installments over the next 36 months.
The shares subject to the option became vested and exercisable according to the following schedule: 25% of the shares subject to the option vested on the first anniversary of the grant date, and the remaining shares vested in equal monthly installments over the next 36 months.
/s/ Paul Quinlan, as attorney-in-fact for Daniel Menold
2023-09-15